NasdaqGM:PTGXBiotechs
Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Shareholder Returns
Protagonist Therapeutics (PTGX) is back on investor watchlists after recent trading moves, with its latest close at US$81.93 highlighting how the market is currently pricing its late stage pipeline and revenue profile.
See our latest analysis for Protagonist Therapeutics.
Recent trading has been choppy, with a 1.9% single day share price decline and a modest 7 day share price gain. However, the 1 year total shareholder return of 111.8% and the very large 3 year total shareholder return of...